The addition of lixisenatide to basal insulin improved glycemic control, especially in patients with controlled fasting plasma glucose, a presenter said at the annual meeting of the European Association for the Study of Diabetes.
In a comparison of placebo to lixisenatide (Lyxumia, Sanofi), the GetGoal-L study subanalysis showed that adding the once-daily prandial glucagon-like peptide-1 receptor agonist lowered HbA1c and reduced weight and self-measured blood glucose profiles. Patients with baseline fasting plasma glucose <6.7 mmol/L demonstrated greater placebo-adjusted reductions than those in the groups characterized by FPG >6.7 mmol/L.
“We’d like to conclude that the addition of the once-daily prandial GLP-1 receptor analog lixisenatide is most effective when FPG is already well controlled by basal insulin,” Josep Vidal, MD, of the endocrinology and nutrition department at the University of Barcelona, said in his presentation. “We think this observation is consistent with the complementary therapeutic effects of basal insulin, mainly on FPG, and the once-daily prandial GLP-1 receptor analog lixisenatide, mainly targeting postprandial glucose.”
Lixisenatide is approved in Europe for the treatment of type 2 diabetes in adults.
“That improved glycemic control with basal insulin comes along with a greater incidence of symptomatic hypoglycemia versus the two higher FPG subgroups, but the incidence of severe hypoglycemia was low and similar among subgroups,” he said.
For more information:
Vidal J. Oral Presentation #6. Presented at: the 49th Annual Meeting of the European Association for the Study of Diabetes; Sept. 24-27, 2013; Barcelona, Spain.
Disclosure: This study was supported by Sanofi.